Amylyx Pharmaceuticals
MA - CambridgePharmaceutical
Focus: Amylyx is a specialized neurology-focused pharmaceutical company commercializing RELYVRIO, a combination of existing products for rare metabolic disorders. The company generates 100% of revenue from this single approved product.
Profile data last refreshed 2h ago · AI intelligence enriched 3w ago
Open Jobs
29+14 this month
Growing — net +14 jobs in 30d
28 jobs added vs 14 removed. Steady team buildout.
Should You Work at Amylyx Pharmaceuticals?
AI assessmentBest suited for commercial and biometrics professionals seeking early-scale impact in a revenue-generating specialty biotech, but R&D candidates should assess pipeline risk tolerance carefully.
Why Work Here
- Immediate revenue generation from approved product RELYVRIO ($198M Part D spending) provides financial stability rare for early-stage biotechs.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$198M Part DGrowing
Peak
Help build intelligence for Amylyx Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.